CN1788740A - Externally-used pain-relieving spray - Google Patents
Externally-used pain-relieving spray Download PDFInfo
- Publication number
- CN1788740A CN1788740A CN 200410098442 CN200410098442A CN1788740A CN 1788740 A CN1788740 A CN 1788740A CN 200410098442 CN200410098442 CN 200410098442 CN 200410098442 A CN200410098442 A CN 200410098442A CN 1788740 A CN1788740 A CN 1788740A
- Authority
- CN
- China
- Prior art keywords
- externally
- relieving
- used pain
- medicinal
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses one kind of analgetic aerosol. The analgetic aerosol includes volatile pubescent angelica oil as the medicinal effective matter and pharmaceutically acceptable supplementary material including filming agent. The medicinal filming agent can raise the transdermal speed and amount of volatile pubescent angelica oil to make volatile pubescent angelica oil take its medicinal effect fast and duratively.
Description
Invention field the present invention relates to a kind of externally-used pain-relieving spray, and the effective substance of this spray is an Angelica grosseserrata volatile oil; Used pharmaceutically acceptable auxiliaries comprises pharmaceutically acceptable film former, feasible patent medicine film behind the spray delivery.This spray is a dermatologic, but pain relieving, detumescence, dissipating blood stasis are used for little joint contusion, ligament, muscle sprain and rheumatalgia.
Background technology
Angelica grosseserrata volatile oil is the volatile oil that the dry root of the heavy peristome Radix Angelicae Sinensis of samphire (Angelia pubescons Moam fbiserrata shan etYuan) obtains through the water distillation.Radix Angelicae Pubescentis has wind-damp dispelling, and the effect of numbness relieving and pain relieving is used for anemofrigid-damp arthralgia, lumbocrural pain.This product is the supernatant liquid of little yellow or rufous, and the special fragrance of Radix Angelicae Pubescentis is arranged, and stores with the passing of time, and the color gradual change is dark.Angelica grosseserrata volatile oil has antiinflammatory action, treats multiple acute or chronic soft tissue injury, laceration of ligament, scapulohumeral periarthritis etc. effectively.
At present, has only Radix Angelicae Pubescentis liniment anodyne (seeing " Drug Standard of Ministry of Public Health of the Peoples Republic of China " the 15) with Angelica grosseserrata volatile oil as the external used medicine of effective substance, method for making adds rose essence 10g, mixing for getting Angelica grosseserrata volatile oil 10g, it is an amount of to add 70% ethanol, stir evenly, reuse 70% ethanol is adjusted total amount to 1000ml, filters, packing, promptly.Effect with pain relieving, detumescence, dissipating blood stasis.Be used for little joint contusion, ligament, muscle sprain and rheumatalgia etc.Angelica grosseserrata volatile oil has volatility, volatilizees easily at skin surface.Solvent for use is 70% ethanol in the Radix Angelicae Pubescentis liniment anodyne, and 70% ethanol also has volatility.Alcoholic acid volatilization also can be taken away the part Angelica grosseserrata volatile oil simultaneously, has quickened the volatilization of Angelica grosseserrata volatile oil.Angelica grosseserrata volatile oil is the effective substance in the Radix Angelicae Pubescentis liniment anodyne, and the volatilization of effective substance causes medicine can not bring into play drug effect enduringly.
Summary of the invention can make things convenient for administration simultaneously in order to make the effective substance can quick, persistent performance drug effect, and the present invention has prepared this externally-used pain-relieving spray.
The present invention is to the investigation of preparation outward appearance, film forming outward appearance, film formation time, spraying character, and screening has added pharmaceutically acceptable film former.After adding pharmaceutically acceptable film former, can form the medicine film behind the spray delivery.Test our surprised discovery by transdermal, add pharmaceutically acceptable film former after effective substance Angelica grosseserrata volatile oil skin transit dose increased several times, make Angelica grosseserrata volatile oil can bring into play drug effect more fully.The raising of Angelica grosseserrata volatile oil skin transit dose, may be because can form one deck medicine film bank at skin surface after the administration, make medicine constantly see through skin, the performance drug effect, this layer medicine film has significantly reduced the volatilization of medicine simultaneously, makes medicine bring into play drug effect lastingly.The medicine film of skin surface has increased the hydration of skin in addition, makes that medicine is transdermal to speed up, and makes medicine bring into play drug effect fast.The present invention has overcome effective substance volatilization in the liniment, the shortcoming of the unendurable performance drug effect that causes.The present invention has measured acceptable solvent preferred by viscosimetric analysis, spray particle diameter in addition.
The present invention relates to a kind of externally-used pain-relieving spray, this medicament spraying agent comprises effective substance and pharmaceutically acceptable auxiliaries.Effective substance is an Angelica grosseserrata volatile oil, and pharmaceutic adjuvant comprises pharmaceutically acceptable film former.
Pharmaceutically acceptable film former is one or more the combination in medicinal natural macromolecular material, the medicinal synthesized polymer material.
Pharmaceutically acceptable film former is preferably one or more the combination in the medicinal synthesized polymer material.
Medicinal natural macromolecular material is preferably cellulose derivative, natural glue.Medicinal natural macromolecular material is preferably ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, arabic gum, Resina persicae, gelatin again.The addition of medicinal natural macromolecular material is preferably 0.00001～0.15g/ml.The addition of medicinal natural macromolecular material is preferably 0.0001～0.1g/ml.
Medicinal synthesized polymer material is vinyl synthetic high polymer polymer, acrylate homopolymer and copolymer.
Medicinal synthesized polymer material is preferably polyvinyl alcohol, Pioloform, polyvinyl acetal, polyvinylpyrrolidone, ethylene vinyl acetate polymer, AEA, acrylic resin.Medicinal synthesized polymer material is polyvinyl alcohol, Pioloform, polyvinyl acetal, polyvinylpyrrolidone, acrylic resin more preferably.Medicinal synthesized polymer material most preferably is polyvinylpyrrolidone.It is 0.001～0.2g/ml that the addition of medicinal synthesized polymer material is preferably.The addition of medicinal synthesized polymer material more preferably is 0.01～0.15g/ml.
Pharmaceutically acceptable film former most preferably is polyvinylpyrrolidone.
Pharmaceutically acceptable auxiliaries also comprises acceptable solvent.Acceptable solvent is preferably water, ethanol, liquid paraffin, ethyl acetate, fatty oil, isopropyl fatty acid ester kind solvent.Acceptable solvent is water, ethanol, isopropyl fatty acid ester kind solvent more preferably.Acceptable solvent most preferably is ethanol.Wherein the isopropyl fatty acid ester kind solvent is preferably isopropyl myristate, Petiolus Trachycarpi is calculated isopropyl ester, linoleic acid isopropyl ester.The isopropyl fatty acid ester kind solvent most preferably is the different and ester of myristic acid.Concentration of alcohol is 40%～100%.
Pharmaceutically acceptable auxiliaries can also comprise aromatic, transdermal enhancer etc. among the present invention.
Aromatic can comprise rose essence, Oleum Caryophylli, Oleum Eucalypti etc. for natural or compound essence spice among the present invention.
Transdermal enhancer can comprise azone, isopropyl alcohol, oleic acid, lecithin etc. for natural or synthetic transdermal enhancer among the present invention.
The present invention makes the external used medicine spray with Angelica grosseserrata volatile oil and pharmaceutically acceptable auxiliaries, and preferred pharmaceutically acceptable film former and acceptable solvent, effectively overcome the shortcoming of liniment, and have the following advantages: the 1) adding of pharmaceutically acceptable film former, effectively reduced the volatilization of effective substance, make the effective substance can persistent performance drug effect, and then fundamentally solved the defective that the liniment agent is difficult to lasting produce effects.2) after the local application, pharmaceutically acceptable film former can increase the hydration of cuticular humidifying and skin, makes the easier skin that sees through of medicine.3) select suitable acceptable solvent for use, effective substance is discharged from substrate fast, see through skin performance drug effect.
Preparation technology of the present invention is: get Angelica grosseserrata volatile oil and add an amount of acceptable solvent mixing, make I liquid.Get pharmaceutically acceptable film former and add an amount of stirring solvent dissolving, make II liquid.I liquid and II liquid merge, and mixing adds acceptable solvent to capacity, and mixing, filtration are promptly.
Embodiment
1. preferred pharmaceutically acceptable film former
The present invention screens the kind and the consumption of pharmaceutically acceptable film former by preparation outward appearance, film formation time, one-tenth not being had the investigation of outward appearance, spraying character.
Sample preparation technology: get Angelica grosseserrata volatile oil 0.1g and add an amount of solvent (solvent species is pressed table 1 and added) mixing, make I liquid.Get pharmaceutically acceptable film former (adding) and add an amount of solvent (pressing table 1 adds) stirring and dissolving, make II liquid by table 1.I liquid and II liquid merge, and mixing adds acceptable solvent (solvent species is pressed table 1 and added), makes it into the 10ml mixing, filters promptly.
The investigation of pharmaceutically acceptable film former kind of table 1 and consumption
Annotate: the PVA polyvinyl alcohol; The PVB polyvinyl butyral resin; The PVP polyvinylpyrrolidone; The EVA ethylene vinyl acetate copolymer; The AEA AEA; The HPC hydroxypropyl cellulose; The EC ethyl cellulose; The HPMC hydroxypropyl emthylcellulose
2. transdermal test
The merit of a kind of externally-used pain-relieving spray of the present invention is energy pain relieving, detumescence, dissipating blood stasis.Be used for little joint contusion, ligament, muscle sprain and rheumatalgia etc., using method is an external preparation for skin.Drug effect depends on transdermal speed of effective substance and transit dose to a great extent.The factor that influences drug transdermal is mainly skin condition, pharmaceutical properties and substrate and forms.Under the identical condition of skin, medicine, select different adjuvants for use, transdermal effect is also just different.Therefore,, designed the transdermal test, added the transdermal situation of pharmaceutically acceptable film former front and back medicine in the investigation side at we's onset position.
Angelica grosseserrata volatile oil is an effective substance of the present invention, and Angelica grosseserrata volatile oil controllable component in preparation, and vapor detection is accurate.By gas phase Angelica grosseserrata volatile oil is detected, a characteristic peak occurred at 14.6 minutes, peak area is bigger, and retention time is stable.Therefore the detection index that the characteristic peak of selecting for use Angelica grosseserrata volatile oil to occur in 14.6 minutes is tested as this transdermal.By this experiment, mainly investigate effective ingredient Angelica grosseserrata volatile oil transdermal amount.
Sample preparation technology:
Comparative example 2: get Angelica grosseserrata volatile oil 0.2g and add an amount of 80% ethanol mixing, add 80% ethanol, make it into the 20ml mixing, filter and promptly to get comparative example 2 samples.
Embodiment 20: get Angelica grosseserrata volatile oil 0.2g and add an amount of 80% ethanol and stir, make I liquid.Get PVP1g and add an amount of 80% ethanol stirring and dissolving, make II liquid.I liquid and II liquid merge, and mixing adds 80% ethanol, make it into the 20ml mixing, filter and promptly get embodiment 20 samples.
Assay method: select 18～22g male ICR mouse (Beijing Vital River Experimental Animals Technology Co., Ltd. provides) for use, put to death.Shave hair, get skin of abdomen, remove subcutaneous tissue.Select Franz diffusion cell (red blue electronics technology center, intelligent transdermal diffusion instrument TP-3 type Nanjing) for use, skin is fixed on the reception bottleneck, 30% ethanol normal saline is housed in the receiving bottle, interior adding amylalcohol is as internal standard substance matter, and adding concentration is 0.2 μ l/ml.The volume of receiving bottle is 17ml.The medicinal liquid for preparing evenly is applied on the skin, and dosage is 100mg.Respectively at taking a sample when 30min, 60min, 120min, 240min after the administration, 10 μ l take a sample at every turn.The transdermal cumulant of Angelica grosseserrata volatile oil is measured in 5 μ l air inlets mutually.For reducing operate miss, operation repetitive three times.1, smears comparative example 2 samples for 2, No. 3; 4, smear embodiment 20 samples for 5, No. 6.The results are shown in Table 2
Table 2 adds the transdermal test of pharmaceutically acceptable film former and compares
3. different solvents is to the influence of medicine viscosity and spray particle diameter
The spray that the present invention is made of jointly Angelica grosseserrata volatile oil and pharmaceutically acceptable auxiliaries.The spray product atomization, the result of use that droplet size of its ejection just and distribution of sizes directly affect it.Viscosity is the inherent character of liquid, is that liquid is during flow to the shape of self component or the opposing of arrangement change.Liquid viscosity is to influence the principal element that spray shapes forms, and also is the key factor of decision mist droplet particle size size, and liquid viscosity increases, and size droplet diameter increases.External used medicine spray of the present invention for this employing manual pump spraying, the pressure of spraying is certain, the solution that viscosity surpasses certain limit possibly can't form spraying, and the solution that forms spraying also not necessarily has the suitable spray shapes and the size of drop, so must carry out viscosity research to acceptable solvent, seek the suitable drug solution of viscosity that is fit to spraying.Select different solvents for use, can influence atomization.In order to make the present invention reach best spray effect, the present invention has carried out the test of viscosity, mist droplet particle size to the sample of different solvents preparation.
Get Angelica grosseserrata volatile oil (taking by weighing) and add the acceptable solvent stirring and evenly mixing, add acceptable solvent again to capacity (10ml) according to table 1.Fill screws manual pump, spraying in spray bottle (the German Pfeiffer of standard atomizing pump 0.05ml screw thread 18/415 company China portion).Observe the medicine character, the spraying character the results are shown in Table 3
The composition of each prescription of table 3 mist agent
Annotate: EtOH ethanol; The EA ethyl acetate; The IPM isopropyl myristate; The IPP isopropyl palmitate; IPL linoleic acid isopropyl ester
Get Angelica grosseserrata volatile oil 1g, add an amount of acceptable solvent stirring and evenly mixing, solubilizer is to capacity 10ml again.
Measure viscosity (method be " 2000 editions two appendix VIG viscosimetries of Chinese pharmacopoeia, first method) with Ping Shi viscometer (Yangzhou, Jiangsu red flag glass apparatus factory), fill is in spray bottle (the German Pfeiffer of standard atomizing pump 0.05ml screw thread 18/415 company China portion), screw manual pump, spray at distance silicone oil paper 10cm place, mist droplet particle size is observed, measured to microscopically, the index of record spraying the results are shown in Table 4.
Table 4 different solvents is to the influence of medicine viscosity and spray particle diameter
Annotate: mixed solvent all mixes according to equal proportion in the table 4.
From above-mentioned experimental result as seen, sample viscosity sample spraying character the best below 5 centipoises; The medicament spraying agent spraying character of sample viscosity between 5 centipoises～10 centipoises is more excellent; Sample viscosity is between 10 centipoises～15 centipoises, and the spraying character still can; Sample viscosity is when 15 centipoises are above, and atomize is not good.When selecting single solvent for use, fatty oil viscosity is big slightly, and atomizing effect is poor, but still can spray.The viscosity of ethanol, ethyl acetate, isopropyl palmitate, isopropyl myristate, linoleic acid isopropyl ester is little, and the sample viscosity of making is below 10 centipoises, and atomizing effect is good.Liquid paraffin is made the sample that solvent is made, and atomizing effect is general.The present invention has also used mixed solvent, mixes with high viscosity solvent by low viscosity solvent, reduces the viscosity of high viscosity solvent, has improved the spraying character.Mix with liquid paraffin respectively as ethanol, isopropyl myristate, ethyl acetate, the viscosity of sample has reduced, and spray particle diameter obviously diminishes, and the spraying character improves.
4. the investigation of transdermal enhancer, aromatic
Some adjuvants have also been added in the present invention, as transdermal enhancer, aromatic etc.Penetration enhancer can infiltrate horny layer, reduces the order that the iuntercellular lipid is arranged; Slough the passage that the iuntercellular lipid forms; Increase the horny layer water content; Reduce the phase rate of transformation of horny layer lipid.The adding of transdermal enhancer can improve the Angelica grosseserrata volatile oil percutaneous rate, shortens time lag, increases the accumulation transmitance.Multiple promoter can be share by a certain percentage, and majority can reach the single promoter effect that is beyond one's reach.Be drug transdermal situation behind the mensuration adding penetration enhancer, we have carried out the transdermal test, and experimental implementation is the same.Accumulative total transmitance when calculating 240min, and transdermal time lag.
Preparation technology of the present invention is: get Angelica grosseserrata volatile oil 0.1g, add an amount of acceptable solvent dissolving.Pharmaceutically acceptable film former is added the acceptable solvent dissolving, join in the Angelica grosseserrata volatile oil mixed liquor, adding transdermal enhancer promoter, aromatic stir evenly, and add acceptable solvent again to capacity 10ml, stir evenly, and filter, promptly.Annotate: pharmaceutically acceptable film former, acceptable solvent, promoter, aromatic all add according to table 5.The results are shown in Table 5
The investigation of table 5 transdermal enhancer, aromatic
The different transdermal enhancers of table 6 are to the influence of Angelica grosseserrata volatile oil transdermal penetration
| Experimental group | Prescription | Receive liquid concentration (μ g/ml) | Accumulation transmitance (%) | Time lag t (h) | |
| Embodiment 48 | 0.01g/ml azone | 0.05g/mlPVP | 42.28 | 71.876 | 0.37 |
| Embodiment 49 | 0.025g/ml azone | 0.05g/mlPVP | 41.76 | 70.992 | 0.40 |
| Comparative example 4 | 0.05g/ml azone | 0.05g/mlPVP | 19.76 | 33.592 | 0.64 |
| Embodiment 50 | 0.01g/ml azone | 0.005g/mlHPC | 36.27 | 61.659 | 0.51 |
| Embodiment 51 | 0.01g/ml azone | 0.005g/mlHPLC | 31.58 | 53.686 | 0.40 |
| Embodiment 52 | 0.05g/ml oleic acid | 0.005g/mlHPC | 29.68 | 50.456 | 0.52 |
| Embodiment 53 | 0.05g/ml isopropyl alcohol | 0.005g/mlHPLC | 27.42 | 46.614 | 0.30 |
| Embodiment 54 | 0.05g/ml oleic acid 0.05g/ml isopropyl alcohol | PVP、HPL、HPLC | 33.75 | 57.375 | 0.34 |
As can be seen from Table 6, add the accumulation transmitance that transdermal enhancer agent (as azone, oleic acid, isopropyl alcohol etc.) can improve Angelica grosseserrata volatile oil.By embodiment as can be known, 1%～2.5% azone, 5% oleic acid, 5% isopropyl alcohol all have short saturating effect to the transdermal of Angelica grosseserrata volatile oil, and 5% azone then has inhibitory action to the transdermal effect of Angelica grosseserrata volatile oil.Can add azone (addition is not higher than 5%), oleic acid, isopropyl alcohol etc. in the present invention as transdermal enhancer.
As the external preparation for skin medicine, invention has increased pharmaceutically acceptable film former by reasonably prescription design, screened acceptable solvent, improved the effective substance Angelica grosseserrata volatile oil greatly and seen through the accumulation transmitance, the stable state transmission rates has also shortened time lag, makes the quick and durable performance drug effect of effective substance energy.
Claims (21)
1. externally-used pain-relieving spray, this pain-easing spray comprises effective substance and pharmaceutically acceptable auxiliaries, it is characterized in that: described effective substance is an Angelica grosseserrata volatile oil; Pharmaceutically acceptable auxiliaries comprises pharmaceutically acceptable film former.
2. externally-used pain-relieving spray according to claim 1 is characterized in that: described pharmaceutically acceptable film former is one or more the combination in medicinal natural macromolecular material, the medicinal synthesized polymer material.
3. externally-used pain-relieving spray according to claim 1 is characterized in that: described pharmaceutically acceptable film former is one or more the combination in the medicinal synthesized polymer material.
4. externally-used pain-relieving spray according to claim 2 is characterized in that: described medicinal natural macromolecular material is cellulose derivative, natural glue.
5. externally-used pain-relieving spray according to claim 2 is characterized in that: described medicinal natural macromolecular material is ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, arabic gum, Resina persicae, gelatin.
6. according to claim 2,3 described externally-used pain-relieving sprays, it is characterized in that: described medicinal synthesized polymer material is vinyl synthetic high polymer polymer, acrylate homopolymer and copolymer.
7. according to claim 2,3 described externally-used pain-relieving sprays, it is characterized in that: described medicinal synthesized polymer material is polyvinyl alcohol, Pioloform, polyvinyl acetal, polyvinylpyrrolidone, ethylene vinyl acetate polymer, AEA, acrylic resin.
8. according to claim 2,3 described externally-used pain-relieving sprays, it is characterized in that: described medicinal synthesized polymer material is polyvinyl alcohol, Pioloform, polyvinyl acetal, polyvinylpyrrolidone, acrylic resin.
9. according to claim 2,3 described externally-used pain-relieving sprays, it is characterized in that: described medicinal synthesized polymer material is a polyvinylpyrrolidone.
10. externally-used pain-relieving spray according to claim 1 is characterized in that: described pharmaceutically acceptable film former is a polyvinylpyrrolidone.
11. externally-used pain-relieving spray according to claim 2 is characterized in that: the addition of medicinal natural macromolecular material is 0.00001～0.15g/ml.
12. externally-used pain-relieving spray according to claim 2 is characterized in that: the addition of medicinal natural macromolecular material is 0.0001～0.1g/ml.
13. externally-used pain-relieving spray according to claim 2 is characterized in that: the addition of medicinal synthesized polymer material is 0.001～0.2g/ml.
14. externally-used pain-relieving spray according to claim 2 is characterized in that: the addition of medicinal synthesized polymer material is 0.01～0.15g/ml.
15. externally-used pain-relieving spray according to claim 1 is characterized in that: described pharmaceutically acceptable auxiliaries also comprises acceptable solvent.
16. externally-used pain-relieving spray according to claim 15 is characterized in that: described acceptable solvent is one or more the combination in water, ethanol, liquid paraffin, ethyl acetate, fatty oil, the isopropyl fatty acid ester kind solvent.
17. externally-used pain-relieving spray according to claim 15 is characterized in that: described acceptable solvent is one or more the combination in water, ethanol, the isopropyl fatty acid ester kind solvent.
18. externally-used pain-relieving spray according to claim 15 is characterized in that: described acceptable solvent is an ethanol.
19. according to claim 16,17 described externally-used pain-relieving sprays, it is characterized in that: described isopropyl fatty acid ester kind solvent is a kind of in isopropyl myristate, isopropyl palmitate, the linoleic acid isopropyl ester and more than one combination.
20. according to claim 16,17 described externally-used pain-relieving sprays, it is characterized in that: described isopropyl fatty acid ester kind solvent is an isopropyl myristate.
21. according to claim 16,17,18 described externally-used pain-relieving sprays, it is characterized in that: described concentration of alcohol is 40%～100%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100984420A CN100348168C (en) | 2004-12-13 | 2004-12-13 | Externally-used pain-relieving spray |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100984420A CN100348168C (en) | 2004-12-13 | 2004-12-13 | Externally-used pain-relieving spray |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1788740A true CN1788740A (en) | 2006-06-21 |
| CN100348168C CN100348168C (en) | 2007-11-14 |
Family
ID=36786984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100984420A Expired - Fee Related CN100348168C (en) | 2004-12-13 | 2004-12-13 | Externally-used pain-relieving spray |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100348168C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109845A (en) * | 2016-05-05 | 2016-11-16 | 中国医学科学院药用植物研究所云南分所 | For treating the Sanguis Draxonis spray of pressure ulcer and inspection thereof and preparation method |
| CN109044973A (en) * | 2018-11-02 | 2018-12-21 | 广东药科大学 | A kind of swelling and pain relieving is spraying |
| CN112369412A (en) * | 2020-10-27 | 2021-02-19 | 广州至简新材料有限公司 | Special plant essential oil fly-expelling spray for dairy cows and preparation method thereof |
-
2004
- 2004-12-13 CN CNB2004100984420A patent/CN100348168C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109845A (en) * | 2016-05-05 | 2016-11-16 | 中国医学科学院药用植物研究所云南分所 | For treating the Sanguis Draxonis spray of pressure ulcer and inspection thereof and preparation method |
| CN106109845B (en) * | 2016-05-05 | 2019-07-26 | 中国医学科学院药用植物研究所云南分所 | For treating the Resina Draconis spray and its inspection and preparation method of pressure sore |
| CN109044973A (en) * | 2018-11-02 | 2018-12-21 | 广东药科大学 | A kind of swelling and pain relieving is spraying |
| CN112369412A (en) * | 2020-10-27 | 2021-02-19 | 广州至简新材料有限公司 | Special plant essential oil fly-expelling spray for dairy cows and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100348168C (en) | 2007-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1133565A (en) | Pernasal composition and pernasal preparation containing the same | |
| CN1210462A (en) | External preparation containing tranilast and process for producing the same | |
| US20180055903A1 (en) | Homeopathic composition comprising hypericum perforatum extract and essential oils for the treatment of neuropathic pain | |
| CN1875960A (en) | A nanoemulsion medicine of eugenol and preparation method thereof | |
| Koshovyi et al. | Pharmaceutical 3D-printing of nanoemulsified eucalypt extracts and their antimicrobial activity | |
| CN101036644A (en) | Pharmaceutical composition containing arctigenin and preparation method | |
| Sampaopan et al. | Formulation development and pharmaceutical evaluation of Lysiphyllum strychnifolium topical patches for their anti-inflammatory potential | |
| CN100348168C (en) | Externally-used pain-relieving spray | |
| CN1989956A (en) | Adapalene gel composition and its preparation | |
| CN1647804A (en) | External medicine spray | |
| CN102657602A (en) | 3,5-dyhydroxyl-4-isopropyl diphenylethene chitosan gel and preparation method thereof | |
| CN1891285A (en) | Chinese medicine composition, and its preparing method and quality control method | |
| EP2178523A2 (en) | Transdermal therapeutic systems which contain the substance anastrozole | |
| CN1543976A (en) | Astragaloside injection preparation and its preparing process | |
| CN100335050C (en) | Compsn. of medication of silybum mariamum | |
| CN1833715A (en) | Skin care gel for skin titillation and prepn. thereof | |
| CN1695649A (en) | Soft capsule of extractive from active ingredient of jingangteng, and preparation method | |
| CN1478465A (en) | Biphenyl diester liquid medicinal composition containing fat | |
| CN1836694A (en) | Medicine composition for treating cardiovascular diseases and preparation method thereof | |
| CN1054529C (en) | High performance and quick effective skin penetrating and slow releasing Chinese medical paste and preparations | |
| CN1250121C (en) | Compound tobacco addict controlling plaster and its preparation method | |
| CN108355138A (en) | A kind of application of azone in drug transdermal promotees to ooze | |
| CN101040864A (en) | Application of paeoniflorin for enriching the blood | |
| CN100341507C (en) | Compound bergenin pills and its preparation method | |
| CN1352985A (en) | Active component of red sage root, its slowly releasing medicine and medical purpose, and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190828 Address after: 712000 Airborne Industrial Park of Beidu Town, Weicheng District, Xianyang City, Shaanxi Province Patentee after: Shaanxi Oriental Kane Pharmaceutical Co., Ltd. Address before: Room 3103, 311 Building, Beili, Huizhong, Chaoyang District, Beijing, 100012 Patentee before: Dongfang Kaien Medicine Sci. & Tech. Co., Ltd., Beijing |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Dongfang Kaien Medicine Sci. & Tech. Co., Ltd., Beijing Document name: Notification of Passing Examination on Formalities |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071114 Termination date: 20201213 |